BMS and AZ to look at cardiprotective effect if dapagliflozin approved in diabetes
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb and AstraZeneca have reported new data supporting the cardiovascular (CV) safety profile of their investigational type 2 diabetes drug, dapagliflozin, and said that if the product is successfully approved in diabetes, they plan to further investigate if it confers a cardioprotective effect.